FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4364380400> ?p ?o ?g. }

• W4364380400 endingPage "10" @default.
• W4364380400 startingPage "10" @default.
• W4364380400 abstract "Background: Sickle cell disease (SCD) is characterized by the presence of sickle hemoglobin, hemolytic anemia, and multi-organ and vaso-occlusive complications that can significantly decrease quality of life.[1] Crizanlizumab, a monoclonal antibody, has been shown to reduce the rate of vaso-occlusive crises (VOCs) compared to placebo in patients ≥16 years with SCD.[2] However, there have been reports of patients experiencing severe pain and subsequent complications within 24 hours of crizanlizumab infusions, and these events are defined as infusion-related reactions (IRRs).[3] IRRs are rare, and most clinicians will have limited experience managing them. Aims: Develop clinical guidelines on the management of IRRs presenting with pain in SCD patients receiving crizanlizumab. Methods: We used the RAND/UCLA modified Delphi process. We convened a geographically diverse, experienced 10-member US physician panel (5 pediatric hematology, 4 adult hematology, 1 transfusion medicine) and reviewed evidence on the management of painful IRRs related to crizanlizumab in patients with SCD. We collaboratively developed a rating form made up of 204 hypothetical patient scenarios assessing how to monitor and treat IRRs that present with new or worsening pain. For each of these scenarios, which described different clinical characteristics (e.g., typical vs atypical SCD pain location, pain severity compared to patient’s typical SCD crisis), we asked how to monitor vital signs, when to change infusion speed or discontinue the infusion, which medications to add, which laboratory tests to order, and whether to escalate care (e.g., emergency department referral). Physicians completed ratings both before and after a virtual meeting in June 2022, during which areas of disagreement were discussed. Consensus was defined as being present when no more than two panelists gave a response that differed significantly from the other 8 panelists. Results: Expert recommendations on how to manage IRRs presenting with pain are delineated in Figure 1. When a patient presents with either chest pain of the same severity or pain in any location more severe than their typical SCD crisis, experts recommend continuous vital sign monitoring, stopping the infusion, ordering laboratory tests including a complete blood count, reticulocyte count, and electrolyte and liver function panels, and escalating post-infusion care. Pain should be treated per a patient’s individualized pain plan or other pain management guidelines. Experts do not recommend treating IRRs that present with pain with IV antihistamines or corticosteroids, which can worsen pain and provoke VOCs. Summary/Conclusion: These recommendations outline how to evaluate and manage IRRs presenting with pain in patients receiving crizanlizumab. A valid, reproducible method was used to develop these guidelines, based on expert consensus informed by current literature and clinical experience. Future research should validate this guidance using clinical data and identify patients at risk for these IRRs.References 1. Kavanagh et al. Pediatrics. 2015;136(4):e1016–25. 2. Ataga et al. N Engl J Med. 2017;376(5):429–39. 3. Safety of crizanlizumab [Internet]. [cited 2020 Oct 26]. Available from: https://www.crizanlizumab.info/" @default.
• W4364380400 created "2023-04-12" @default.
• W4364380400 creator A5002276026 @default.
• W4364380400 creator A5003193572 @default.
• W4364380400 creator A5031866680 @default.
• W4364380400 creator A5033950297 @default.
• W4364380400 creator A5038189026 @default.
• W4364380400 creator A5044368358 @default.
• W4364380400 creator A5052390444 @default.
• W4364380400 creator A5053559074 @default.
• W4364380400 creator A5059254756 @default.
• W4364380400 creator A5074285507 @default.
• W4364380400 creator A5075251163 @default.
• W4364380400 creator A5080294977 @default.
• W4364380400 creator A5087138036 @default.
• W4364380400 date "2023-04-01" @default.
• W4364380400 modified "2023-10-14" @default.
• W4364380400 title "5613436 EXPERT CONSENSUS ON THE MANAGEMENT OF INFUSION-RELATED REACTIONS (IRRS) PRESENTING WITH PAIN IN PATIENTS RECEIVING CRIZANLIZUMAB" @default.
• W4364380400 doi "https://doi.org/10.1097/01.hs9.0000928196.80128.ee" @default.
• W4364380400 hasPublicationYear "2023" @default.
• W4364380400 type Work @default.
• W4364380400 citedByCount "0" @default.
• W4364380400 crossrefType "journal-article" @default.
• W4364380400 hasAuthorship W4364380400A5002276026 @default.
• W4364380400 hasAuthorship W4364380400A5003193572 @default.
• W4364380400 hasAuthorship W4364380400A5031866680 @default.
• W4364380400 hasAuthorship W4364380400A5033950297 @default.
• W4364380400 hasAuthorship W4364380400A5038189026 @default.
• W4364380400 hasAuthorship W4364380400A5044368358 @default.
• W4364380400 hasAuthorship W4364380400A5052390444 @default.
• W4364380400 hasAuthorship W4364380400A5053559074 @default.
• W4364380400 hasAuthorship W4364380400A5059254756 @default.
• W4364380400 hasAuthorship W4364380400A5074285507 @default.
• W4364380400 hasAuthorship W4364380400A5075251163 @default.
• W4364380400 hasAuthorship W4364380400A5080294977 @default.
• W4364380400 hasAuthorship W4364380400A5087138036 @default.
• W4364380400 hasBestOaLocation W43643804001 @default.
• W4364380400 hasConcept C126322002 @default.
• W4364380400 hasConcept C141071460 @default.
• W4364380400 hasConcept C177713679 @default.
• W4364380400 hasConcept C194828623 @default.
• W4364380400 hasConcept C2776135927 @default.
• W4364380400 hasConcept C2776890885 @default.
• W4364380400 hasConcept C2778248108 @default.
• W4364380400 hasConcept C2779134260 @default.
• W4364380400 hasConcept C512399662 @default.
• W4364380400 hasConcept C71924100 @default.
• W4364380400 hasConceptScore W4364380400C126322002 @default.
• W4364380400 hasConceptScore W4364380400C141071460 @default.
• W4364380400 hasConceptScore W4364380400C177713679 @default.
• W4364380400 hasConceptScore W4364380400C194828623 @default.
• W4364380400 hasConceptScore W4364380400C2776135927 @default.
• W4364380400 hasConceptScore W4364380400C2776890885 @default.
• W4364380400 hasConceptScore W4364380400C2778248108 @default.
• W4364380400 hasConceptScore W4364380400C2779134260 @default.
• W4364380400 hasConceptScore W4364380400C512399662 @default.
• W4364380400 hasConceptScore W4364380400C71924100 @default.
• W4364380400 hasIssue "S1" @default.
• W4364380400 hasLocation W43643804001 @default.
• W4364380400 hasLocation W43643804002 @default.
• W4364380400 hasLocation W43643804003 @default.
• W4364380400 hasOpenAccess W4364380400 @default.
• W4364380400 hasPrimaryLocation W43643804001 @default.
• W4364380400 hasRelatedWork W1967880379 @default.
• W4364380400 hasRelatedWork W2025193597 @default.
• W4364380400 hasRelatedWork W2042489430 @default.
• W4364380400 hasRelatedWork W2048808494 @default.
• W4364380400 hasRelatedWork W2053221007 @default.
• W4364380400 hasRelatedWork W2083479052 @default.
• W4364380400 hasRelatedWork W2110240774 @default.
• W4364380400 hasRelatedWork W2143906584 @default.
• W4364380400 hasRelatedWork W2427772244 @default.
• W4364380400 hasRelatedWork W2490701021 @default.
• W4364380400 hasVolume "7" @default.
• W4364380400 isParatext "false" @default.
• W4364380400 isRetracted "false" @default.
• W4364380400 workType "article" @default.